Brief: Shenzhen Hepalink Pharmaceutical Says Inhixa Approved For Sales In Bosnia & Herzegovina
10/06/2021 10:29
June 10 (Reuters) - Shenzhen Hepalink Pharmaceutical Group
Co Ltd 002399.SZ :
* SHENZHEN HEPALINK PHARMACEUTICAL-INHIXA APPROVED BY AGENCY
FOR
MEDICINAL PRODUCTS & MEDICAL DEVICES OF BOSNIA & HERZEGOVINA FOR
SALES
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA